Virpax Pharmaceuticals, Inc.
Other OTCTotal Valuation
Virpax Pharmaceuticals, Inc. carries a market capitalization of 497.00, placing it among publicly traded companies globally. Its enterprise value stands at -524,297.00, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 497.00 |
| Enterprise Value | -524,297.00 |
Share Statistics
Virpax Pharmaceuticals, Inc. currently has 595,503.00 shares outstanding.
| Shares Outstanding | 595,503.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.01 |
| P/TBV Ratio | -1.08 |
| P/FCF Ratio | -0.06 |
| P/OCF Ratio | -0.06 |
Financial Position
Virpax Pharmaceuticals, Inc. maintains a current ratio of 0.63, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.63 |
| Quick Ratio | 0.61 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -116.43 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -215.80 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Virpax Pharmaceuticals, Inc.'s stock has declined approximately -99.87879% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.
| Beta (5Y) | N/A |
| 52-Week Price Change | -99.87879% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -12.08M, while operating income came in at -12.08M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -12.08M |
| Pretax Income | -12.07M |
| Net Income | -12.07M |
| EBITDA | -12.08M |
| EBIT | -12.08M |
| Earnings Per Share (EPS) | -115.94 |
Balance Sheet
Total book value stands at -71.61M, with working capital of -913,760.00 providing operational flexibility.
| Cash & Cash Equivalents | 1.51M |
| Total Debt | N/A |
| Net Debt | -1.51M |
| Equity (Book Value) | -71.61M |
| Book Value Per Share | -688.04 |
| Working Capital | -913,760.00 |
Cash Flow
Virpax Pharmaceuticals, Inc. produced -16.71M in operating cash flow over the past twelve months.
| Operating Cash Flow | -16.71M |
| Capital Expenditures | N/A |
| Free Cash Flow | -16.71M |
| FCF Per Share | -160.58 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -918.77 |
| FCF Yield | -1,690.29 |
Stock Splits
Virpax Pharmaceuticals, Inc.'s most recent stock split took place on March 21, 2025 with a 25:1 split ratio.
| Last Split Date | 3/21/2025 |
| Split Ratio | 25:1 |
Scores
Virpax Pharmaceuticals, Inc. posts an Altman Z-Score of -90.54, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -90.54 |